Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 10/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.37 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.37 |
| ▸ | TLR4 | O00206 | 2/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25113905 | 0.86 | TLR8 (0.40) | TLR8TLR7TLR9TLR4PDE4D | |
| SCHEMBL26762009 | 0.82 | TLR8 (0.37) | TLR8TLR7TLR9TLR4PDE4D | |
| SCHEMBL26762028 | 0.80 | PDE4D (0.43) | TLR8TLR7TLR9TLR4PDE4D | |
| SCHEMBL23717259 | 0.78 | PDE4D (0.35) | TLR8TLR7TLR9TLR4PDE4D | |
| SCHEMBL29303193 | 0.76 | KDM4E (0.32) | — | |
| SCHEMBL26482524 | 0.73 | TLR8 (0.44) | TLR8 | |
| SCHEMBL2428877 | 0.71 | TLR8 (0.35) | TLR8TLR7TLR9TLR4PDE4D | |
| SCHEMBL22041254 | 0.70 | KDM5A (0.38) | TLR8 | |
| SCHEMBL2428960 | 0.68 | GRM2 (0.38) | TLR8TLR7TLR9TLR4PDE4D | |
| SCHEMBL13961185 | 0.68 | TLR8 (0.36) | TLR8TLR7TLR9TLR4PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365525-A1 | ANTIVIRAL COMPOUNDS | ENANTA PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230365525-A1 | ANTIVIRAL COMPOUNDS | ENANTA PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230357258-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230357258-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357258-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ACE, HPRT1, ACE2 | TLR8 1278/4885TLR7 269/4885TLR9 550/4885 |
| US-20230365525-A1 | ANTIVIRAL COMPOUNDS | ACE, ZC3HAV1, SARS1 | TLR8 1501/4885TLR7 238/4885TLR9 318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.